Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-07-03 Governance Information
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is titled '会计师事务所选聘制度' which translates to 'Accounting Firm Selection System'. It details the procedures, requirements, and governance related to the selection and appointment of the company's accounting firm. It includes sections on the selection process, quality requirements, supervision, and penalties. There are no financial statements, audit opinions, or actual audit reports included. The document is a policy or governance document related to audit firm selection rather than an audit report or annual report. It is not a certification or a brief announcement but a detailed internal governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2025-07-03 Chinese
董事会战略委员会工作细则
Governance Information Classification · 95% confidence The document is titled '董事会战略委员会工作细则' which translates to 'Board Strategic Committee Working Rules'. It details the composition, responsibilities, meeting procedures, and authority of the company's board strategic committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, or other report types. It is a governance-related document describing internal board committee rules and procedures. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report but the actual governance rules text.
2025-07-03 Chinese
内幕信息知情人登记管理办法
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理办法' which translates to 'Insider Information Insider Registration Management Measures'. It is a detailed internal policy document issued by the company's board regarding the management and registration of insider information holders. The content includes definitions, responsibilities, procedures, and legal obligations related to insider information management. There are no financial statements, no earnings data, no voting results, no audit opinions, no capital changes, no legal proceedings updates, no merger or acquisition announcements, and no report publication notices. The document is a governance-related internal regulation issued by the board, focusing on compliance and internal control over insider information. Therefore, it fits best under Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, not a mere announcement or certification, so it is not RPA or RNS. Hence, the classification is CGR with high confidence.
2025-07-03 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, qualifications, duties, nomination, election, and responsibilities of independent directors in the company. It references relevant laws, regulations, and stock exchange rules (Beijing Stock Exchange). The document is a governance-related policy or internal regulation document rather than a financial report, announcement of voting results, or management change. It is not a report of financial results, audit, or legal proceedings. It is a detailed governance framework document about board structure and director duties. Therefore, it fits best under Governance Information (CGR). The document length is over 10,000 characters, indicating it is a full policy document, not a brief announcement or notice.
2025-07-03 Chinese
第三届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the third board of directors of Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to governance and board-related matters such as amendments to company bylaws, governance system revisions, and board member elections. The document does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is primarily about board decisions and governance changes. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4079 characters, which is sufficient for a detailed board meeting resolution announcement, not a brief report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2025-07-03 Chinese
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled '利润分配管理制度' which translates to 'Profit Distribution Management System'. It details the company's policies and procedures regarding profit distribution, including dividend policies, decision-making processes, and supervisory mechanisms. It is a formal policy document approved by the board and to be submitted to the shareholders. The document does not contain financial statements or results, nor is it an announcement of a report publication. It is not a regulatory filing or certification. It is a governance-related document outlining internal rules and policies on profit distribution and shareholder returns. Therefore, it fits best under Governance Information (CGR). The document length is 3465 characters, which is relatively short but contains substantive policy content rather than just an announcement.
2025-07-03 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.